Wei Wen Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wei Wen Lim has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Antony Wilks Burgess
Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research
1 shared publication - Belinda Lee
Department of Medical Oncology, Peter MacCallum Cancer Centre, VIC, Australia
1 shared publication - Frédéric Hollande
Collaborative Centre for Genomic Cancer Medicine, University of Melbourne, Melbourne, Australia
1 shared publication - Michael Christie
The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia
1 shared publication - Paul M. Nguyen
Victorian Comprehensive Cancer Centre, University of Melbourne Centre for Cancer Research, Melbourne, VIC 3000, Australia
1 shared publication - Peter Gibbs
Faculty of Medicine, Dentistry and Health Sciences, Melbourne Medical School, University of Melbourne, Parkville, VIC 3010, Australia
1 shared publication
Latest Publications
- Open Access
The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. While immortalized cancer cell lines and genetically engineered murine models have increased our understanding of PDAC tumorigenesis, they do not recapitulate inter- and intra-patient heterogeneity. PDAC patient derived organoid (PDO) biobanks have overcome this hurdle, and provide an opportunity for the high throughput screening of potential new therapies. This review provides a summary of the PDAC PDO biobanks established to date, and discusses how they have advanced our understanding of PDAC biology. Looking forward, the development of coculturing techniques for specific immune or stromal cell populations will enable a better understanding of the crosstalk that occurs within the tumor microenvironment, and the impact of this crosstalk on treatment response.
Open AccessThe Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. While immortalized cancer cell lines and genetically engineered murine models have increased our understanding of PDAC tumorigenesis, they do not recapitulate inter- and intra-patient heterogeneity. PDAC patient derived organoid (PDO) biobanks have overcome this hurdle, and provide an opportunity for the high throughput screening of potential new therapies. This review provides a summary of the PDAC PDO biobanks established to date, and discusses how they have advanced our understanding of PDAC biology. Looking forward, the development of coculturing techniques for specific immune or stromal cell populations will enable a better understanding of the crosstalk that occurs within the tumor microenvironment, and the impact of this crosstalk on treatment response.